On July 9, Afsaneh Beschloss, RockCreek Group founder & CEO, joined ‘Closing Bell Overtime’ on CNBC to talk about the latest round of tariff threats. President Trump reiterated his stance on the August 1 deadline for new tariffs and stated on Truth Social that “no extensions will be granted.” Still, market volatility remained low, and stocks have been stable. Beschloss believes that tariffs themselves are not inherently negative; they can be useful in promoting more equitable trade, especially when other countries engage in unfair trade practices. The main concern lies in the way that tariff changes are being communicated and the accompanying drama.
Beschloss particularly highlighted the President’s mention of a potential 100% tariff on pharmaceuticals down the line, which she described as potentially disastrous for every person due to the essential nature of these products and the long production times for pharmaceutical companies within the US She stressed that most companies require greater certainty regarding tariffs, permitting, and regulations before committing to production in the US. According to Grand View Research, the global pharmaceutical market size was estimated at $1.645 trillion in 2024 and is projected to reach $2.350 trillion by 2030, growing at a CAGR of 6.12% from 2025 to 2030. The market is driven by rising chronic disease prevalence, aging populations, and increased healthcare spending.
That being said, we’re here with a list of the 13 best low priced pharma stocks to buy now.
A biopharmaceutical research laboratory filled with scientists, illuminated by the glow of their equipment.
Methodology
We sifted through the Finviz stock screener to compile a list of the top pharma stocks under $20 as of July 14. We then selected the 13 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q1 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
13 Best Low Priced Pharma Stocks to Buy Now
13. Viatris Inc. (NASDAQ:VTRS)
Share Price as of July 14: $9.14
Number of Hedge Fund Holders: 28
Viatris Inc. (NASDAQ:VTRS) is one of the best low priced pharma stocks to buy now. On June 27, Viatris received approval from China’s National Medical Products Administration/NMPA for Yupelri (revefenacin) inhalation solution for the maintenance treatment of chronic obstructive pulmonary disease/COPD.
Yupelri is the first ever once-daily nebulized long-acting muscarinic antagonist/LAMA approved in China for COPD. Yupelri’s mechanism of action involves inhibiting M3 receptors in the smooth muscle, leading to bronchodilation.
This milestone triggers a one-time payment of $7.5 million from Viatris to Theravance Biopharma Inc. (NASDAQ:TBPH), which is expected in Q3 2025. Theravance Biopharma is also eligible to receive up to an additional $37.5 million in sales-related milestones and escalating royalties ranging from 14% to 20% on net sales of Yupelri in China.
Viatris Inc. (NASDAQ:VTRS) is a healthcare company that operates in 4 segments: Developed Markets, Greater China, JANZ, and Emerging Markets. Theravance Biopharma Inc. (NASDAQ:TBPH) is a biopharmaceutical company that develops and commercializes medicines in the US.
12. Aclaris Therapeutics Inc. (NASDAQ:ACRS)
Share Price as of July 14: $1.58
Number of Hedge Fund Holders: 35
Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the best low priced pharma stocks to buy now. On June 23, Aclaris Therapeutics initiated a placebo-controlled Phase 1a/1b program for its investigational bispecific antibody, called ATI-052. This program follows the recent IND clearance from the US FDA for ATI-052.
The Phase 1a portion will involve single ascending dose/SAD and multiple ascending dose/MAD studies in healthy volunteers to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered ATI-052. ATI-052 is designed as a potential best-in-class bispecific anti-thymic stromal lymphopoietin/TSLP and anti-interleukin-4 receptor/IL-4R antibody.
The design allows for high binding affinity and dual blockade of both upstream TSLP receptor signal transduction and downstream IL-4R activation. The dual targeting selectively inhibits central proinflammatory pathways involved in Th2-mediated inflammation and allergic diseases by blocking TSLP, which is at the top of the inflammatory cascade, and both downstream IL-4 and IL-13, which are key cytokines in these conditions.
Aclaris Therapeutics Inc. (NASDAQ:ACRS) is a clinical-stage biopharmaceutical company that develops novel drug candidates for immune-inflammatory diseases in the US.
